- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06748157
Ei-invasiivinen mediaanihermostimulaatio eteistakyarytmioiden vaimentamiseksi eteisvärinän katetriablaation jälkeen (NEUROPULSE)
Determine the role of vagal/median nerve stimulation using the CardiaCare RR2 home care wearable neuromodulation system on suppressing atrial arrhythmias and related symptoms in patients who have undergone AF ablation. The study population will be comprised of adults (age ≥18 yrs.) who have undergone AF ablation for paroxysmal or persistent AF.
The study will assess the ability of neuromodulation, using the CardiaCare RR2 home care wearable, to suppress the following:
- early (0-2 months) post-ablation arrhythmias that occur in the immediate post-ablation time period
- AF/AT/AFL recurrences between months 2-6 post-ablation.This is a prospective, controlled, double-blind, randomized trial. The first 15 patients will not be randomized and will receive the active median/vagal stimulation only (open label).
The Study will be conducted in up to 1 clinical site in the United States. This study will have 1:1 randomization (active median/vagal stimulation vs sham). The study has been given NSR designation from FDA--NO IDE.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Study will include continuous ECG assessment at 2 (0 for the first 15 patients, open label), 6 and 22 weeks from enrollment for 2 weeks (for 4 weeks at the first measurement for the first 15 patients, open label) and at least daily single lead ECG assessments throughout the follow up period. The ECG's generated can be viewed by physicians only to assess the frequency of RR2 treatments and will not be used to alter any other aspects of standard of care, including medical management, which will continue according to standard of care throughout the study. Patients and investigators will be blinded during the trial. Patients with paroxysmal or persistent AF undergoing AF ablation will be recruited post ablation procedure during hospitalization. During screening/baseline visit, eligible patients will be randomized to either an active treatment or a sham group (1:1 accordingly). The first 15 eligible patients will not be randomized and will receive the active median/vagal stimulation only (open label).
Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users. Patients will be ordered to measure at home, 2 min ECG measurements with the RR2 system, two times a day throughout the study and when feeling symptoms suspected related to AF (AF/AT/PAC).
In addition, Patients will be instructed to perform Neuromodulation sessions with the RR2 home care device. Once a day for the first 2 weeks followed by three times per week for the remaining duration of the study. Additional treatments, up to once daily, will be added during this period in case the patient feels symptom, verified on single lead ECG and site staff.
Treatments will be conducted for a period of 6 months. During the study, the patients will continue to take Standard of care medication. Medications will be recorded throughout the study.
Patient Diary will be dispensed and or APP diary questioners will be used by the subject in order to document symptoms suspected as related to arrhythmia events.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
New York
-
New York, New York, Yhdysvallat, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria
- Men and women ages ≥18 years
- Patients planned to undergo or undergoing AF ablation for paroxysmal or persistent AF and able to be randomized within 48 hours of the ablation procedure.
- Ability and willingness to sign an informed consent form.
- Ability and willingness to use CardiaCare RR2 device, continuous ECG monitoring, and has an available SmartPhone.
Exclusion Criteria
- Rheumatic heart disease
- Extensive atrial disease (* some patients may be determined to be screen failures following the ablation procedure).
- Moderate to severe mitral stenosis or history of mitral valve replacement
- Pacemaker or CRTD or any implanted electrical stimulating device
- Unilateral or bilateral vagotomy
- Peripheral neuropathy affecting the tested upper extremity.
- Severe heart failure (New York Heart Association Class III or IV) within 90 days.
- Recent (within 90 days) stroke or transient ischemic attack.
- Recent (within 90 days) myocardial infarction.
- Pregnancy or breast feeding.
- Life expectancy <1 year for any medical condition
- Currently enrolled in another study that would interfere with this study
- Unsuitable for participating in the study according to attending physician
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Active Comparator: Participants with CardiaCare RR2
Participants undergoing Neuromodulation Sessions (mNVS) and Active Median/Vagal Stimulation. Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users. |
CardiaCare has developed a wrist band that delivers non-invasive neuromodulation to the median nerve to elicit a vagal response (Median-Vagus nerve stimulation-mVNS). The device is in the post-prototype development stage and is ready for human clinical trials. The CardiaCare RR2 device has already been approved by the IRB of the Chaim Sheba Medical Center, IL and the IL MOH (Ministry of Health) in an already completed pilot clinical trial for modulating AF. |
|
Huijausvertailija: Participants with Sham Device
Sham device will be dispensed, which will create a sensation but not provide therapy |
Sham device will be dispensed, which will create a sensation but not provide therapy |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
AF/AFL occurrence
Aikaikkuna: at 2-months and 6-months post-ablation procedure
|
Burden of AF/AFL (defines as 30 seconds or longer) during the 2-months and 6-months period after ablation measured using ECG-patch monitoring and daily RR2 single lead ECG. |
at 2-months and 6-months post-ablation procedure
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Ensiapukäyntien määrä
Aikaikkuna: 6 kuukautta ablaation jälkeen
|
6 kuukautta ablaation jälkeen
|
|
|
Sairaalahoitojen määrä
Aikaikkuna: 6 kuukautta ablaation jälkeen
|
6 kuukautta ablaation jälkeen
|
|
|
Kardiversioiden lukumäärä
Aikaikkuna: 6 kuukautta ablaation jälkeen
|
6 kuukautta ablaation jälkeen
|
|
|
Ablaatio-uusien määrä
Aikaikkuna: 6 kuukautta ablaation jälkeen
|
6 kuukautta ablaation jälkeen
|
|
|
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
Aikaikkuna: 2-month and 6-month post-ablation procedure
|
Time to first AT or AF recurrence measured by CardiaCare RR2 |
2-month and 6-month post-ablation procedure
|
|
Number of arrythmia occurrences
Aikaikkuna: 2-month and 6-month post-ablation procedure
|
Burden of all arrythmias between 2- and 6-months period after ablation will be measured using 2 weeks ECG-patch monitoring and daily RR2 single lead ECG. |
2-month and 6-month post-ablation procedure
|
|
Number of Atrial Arrythmia Symptoms
Aikaikkuna: 6-month post-ablation procedure
|
Difference in Atrial Arrythmia Symptoms during the 6 months period after ablation. |
6-month post-ablation procedure
|
|
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
Aikaikkuna: 6 months post-ablation
|
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence during the 6-months period after ablation. |
6 months post-ablation
|
|
Quality of Life measured using The European Heart Rhythm Association (EHRA) score
Aikaikkuna: Baseline, 2-months, and 6-months
|
The investigators will assess the change in EHRA symptom scale. The EHRA score ranges from 1 to 4. Higher scores indicate more severe symptoms. |
Baseline, 2-months, and 6-months
|
|
Quality of Life measured using Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Score
Aikaikkuna: Baseline, 2-months, and 6-months
|
The AFEQT is a questionnaire assessing quality of life and symptoms in atrial fibrillation patients. It covers four subscales: patient symptoms, daily activities, treatment concerns, and treatment satisfaction. Subscales from 0-100, with Full Scale range from 0 to 100, with higher scores indicating better quality of life and fewer symptom burdens. |
Baseline, 2-months, and 6-months
|
|
Change in PAC/AT/AFL before and after treatment with RR2
Aikaikkuna: Baseline and 6-month post-ablation
|
Change, such as increase or decrease, in incidence/frequency of atrial arrhythmias before and after treatment with study device. |
Baseline and 6-month post-ablation
|
|
Change in Heart Rate Variability (HRV)
Aikaikkuna: Baseline and 6-month post-ablation
|
Heart rate variability (HRV) is the variation in the time interval between consecutive heartbeats. Higher HRV indicates better cardiovascular function and stress resilience. |
Baseline and 6-month post-ablation
|
Yhteistyökumppanit ja tutkijat
Yhteistyökumppanit
Tutkijat
- Päätutkija: Vivek Reddy, MD, Icahn School of Medicine at Mount Sinai
- Päätutkija: Mohit Turagam, MD, Icahn School of Medicine at MS
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- STUDY-24-00641
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .